Recently, AHCY-driven mechanisms have been discussed, such as the treatment of liver carcinoma cells (HepG2) with AHCY inhibitors, where the DNA damage response is predicted to be enhanced by endogenous genotoxicity due to DNA damage and subsequent perturbation of the cellular epigenome20; however, the mechanisms by which AHCY affects cancer are still elusive. The gene discussed is AHCY; the disease is hepatocellular carcinoma.